Summary of In a Major Shift, Cancer Drugs Go ‘Tissue-Agnostic’

Looking for the article?
We have the summary! Get the key insights in just 5 minutes.

In a Major Shift, Cancer Drugs Go ‘Tissue-Agnostic’ summary
Start getting smarter:
or see our plans

Rating

9 Overall

10 Importance

10 Innovation

8 Style


Recommendation

Ken Garber reports on a breakthrough in the treatment of cancer. He explains so-called “tissue-agnostic” drugs in thorough detail, proving his longstanding experience as a science writer. He uses complex medical terms to discuss biomedical mechanisms and drug development. However, he manages to break down the essential information for a general audience. getAbstract recommends this article to anyone interested in new developments in cancer treatment.

In this summary, you will learn

  • What is special about tissue-agnostic drugs,
  • How they target specific genetic markers in tumors and
  • Why their development promises to be a game-changer in cancer therapy.
 

About the Author

Ken Garber is a science writer in Ann Arbor, Michigan with longstanding experience covering biology and medicine. He has written for Science, Nature, Nature Biotechnology and Nature Medicine. He is also a contributing correspondent for the Journal of the National Cancer Institute.

 

Summary

What are tissue-agnostic drugs?

Until recently, doctors treated cancerous tumors with a drug regimen that was dependent on the type of tissue the tumor originated from (e.g. breast, prostate, lung or skin). Novel, “tissue-agnostic” drugs act on tumors independent of their tissue of origin. They can attack any solid tumor presenting a specific genetic marker.


More on this topic

Customers who read this summary also read

Technology Quarterly: Targeting Tumours
8
The Organoid Architect
9
Turning Piglets Into Personalized Avatars for Sick Kids
9
The Cancer Tree
8
The Greatest Hits of the Human Genome
8
Power Couple: Science and Technology
8

Related Channels

Comment on this summary